Agilent Technologies, Inc. - 10-Q Summary (Q2 FY2025)
Business Context and Reporting Period
This filing covers the quarterly period ended April 30, 2025 (Fiscal Q2 2025). Agilent Technologies, Inc. is a global leader in life sciences, diagnostics, and applied markets. In November 2024, the company reorganized its operations into three new reportable segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. All historical data has been recast to reflect this new structure.
Key Financial Metrics
| Metric (in millions) | Q2 2025 | Q2 2024 | 6 Months 2025 | 6 Months 2024 |
|---|---|---|---|---|
| Total Net Revenue | $1,668 | $1,573 | $3,349 | $3,231 |
| Net Income | $215 | $308 | $533 | $656 |
| Diluted EPS | $0.75 | $1.05 | $1.86 | $2.23 |
| Operating Income | $300 | $363 | $676 | $747 |
| Operating Margin | 18.0% | 23.1% | 20.2% | 23.1% |
| Free Cash Flow (Est.) | $441 (6mo) | $625 (6mo) | Calculated as Operating Cash Flow ($652M) minus CapEx ($211M) | |
| Cash & Equivalents | $1,486 | $1,329 | As of April 30, 2025 vs Oct 31, 2024 | |
| Total Debt | $3,495 | $3,390 | Short-term ($146M) + Long-term ($3,349M) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 6% year-over-year (Q2) and 4% (6 months). Growth was driven by the Life Sciences and Diagnostics Markets (+8%) and Agilent CrossLab (+7%) segments, partially offset by a decline in Applied Markets (-1%).
- Profitability Decline: Net income decreased 30% in Q2 and 19% over six months. Operating margins contracted by 5 percentage points (Q2) and 3 percentage points (6 months) due to restructuring costs, unfavorable product mix, and currency headwinds.
- Restructuring Impact: The company recorded $56 million in restructuring expenses in Q2 2025 related to a new workforce reduction plan (FY25 Plan) announced in the quarter. This significantly impacted operating income.
- Investment Losses: Other income (expense) included a $28 million net loss on equity securities and a $15 million impairment of investments in Q2 2025.
- Currency Impact: Foreign currency movements had an unfavorable impact on revenue growth of 2 percentage points in Q2 and 1 percentage point for the six-month period.
Guidance, Outlook, and Risks
- Tariff Risks: Management anticipates that recent tariff changes announced in April 2025 will have a significant adverse impact on costs of revenue in the second half of fiscal 2025. The company expects to mitigate this impact by year-end through supply chain optimization and pricing actions.
- Government Funding: Recent headcount and funding reductions at U.S. federal agencies have adversely impacted business, particularly in the academia and government end markets.
- Capital Allocation: The company continues to return capital to shareholders. In the six months ended April 30, 2025, it repurchased $255 million of stock and paid $141 million in dividends. A quarterly dividend of $0.248 per share was declared for payment in July 2025.
- Outlook: Management remains optimistic about long-term growth in key end markets despite near-term macroeconomic constraints and tariff headwinds.
Investor Verification Checklist
- Restructuring Execution: Verify the timeline and cost savings realization of the new FY25 restructuring plan ($56M expense recorded).
- Tariff Mitigation: Assess the company's ability to pass on cost increases to customers and the specific impact on H2 2025 margins.
- Investment Portfolio: Review the nature of the $15M investment impairment and $28M unrealized loss on equity securities to determine if these are recurring or one-time items.
- Applied Markets Recovery: Monitor the Applied Markets segment, which saw revenue declines, for signs of stabilization in the chemical and government sectors.
- Working Capital Trends: Note the increase in Days Sales Outstanding (DSO) to 74 days and the cash usage in inventory ($41M) as the company builds stock ahead of potential tariff implementations.